



US00D860451S

(12) **United States Design Patent**  
**Smith et al.**

(10) **Patent No.:** **US D860,451 S**

(45) **Date of Patent:** **\*\* Sep. 17, 2019**

(54) **IMPLANT REMOVAL TOOL**

(71) Applicant: **Intarcia Therapeutics, Inc.**, Boston, MA (US)

(72) Inventors: **Jay S. Smith**, Wellesley Hills, MA (US); **Michael R. Cole**, Stratham, NH (US)

(73) Assignee: **Intarcia Therapeutics, Inc.**, Boston, MA (US)

(\*\*) Term: **15 Years**

(21) Appl. No.: **29/566,822**

(22) Filed: **Jun. 2, 2016**

(51) **LOC (12) Cl.** ..... **24-02**

(52) **U.S. Cl.**  
USPC ..... **D24/143**

(58) **Field of Classification Search**  
USPC ..... D24/143-144, 147, 133, 155; D8/57;  
604/59-60, 73

(Continued)

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

1,655,158 A 1/1928 Muir  
2,110,208 A 3/1938 Eggert

(Continued)

**FOREIGN PATENT DOCUMENTS**

DE 00000635692 A 9/1936  
EP 0079405 5/1983

(Continued)

**OTHER PUBLICATIONS**

Palmeri et al., "5-Fluorouracil and recombinant  $\alpha$ -interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," J. Chemotherapy 2(5):327-330 (Oct. 1990).

(Continued)

*Primary Examiner* — Wan Laymon

(74) *Attorney, Agent, or Firm* — Brian C. Trinquet;  
Gordon R. Moriarty; Lathrop Gage LLP

(57) **CLAIM**

The ornamental design for an implant removal tool, as shown and described.

**DESCRIPTION**

FIG. 1 is a perspective view of an embodiment of a design for an implant removal tool;

FIG. 2 is a front view of the design for the implant removal tool of FIG. 1;

FIG. 3 is a back view of the design for the implant removal tool of FIG. 1;

FIG. 4 is a first side view of the design for the implant removal tool of FIG. 1;

FIG. 5 is a second side view of the design for the implant removal tool of FIG. 1;

FIG. 6 is a top view for the design for the implant removal tool of FIG. 1;

FIG. 7 is a bottom view for the design of the implant removal tool of FIG. 1;

FIG. 8 is a perspective view of another embodiment of a design for an implant removal tool;

FIG. 9 is a front view of the design for the implant removal tool of FIG. 8;

FIG. 10 is a back view of the design for the implant removal tool of FIG. 8;

FIG. 11 is a first side view of the design for the implant removal tool of FIG. 8;


FIG. 12 is a second side view of the design for the implant removal tool of FIG. 8;

FIG. 13 is a top view for the design for the implant removal tool of FIG. 8; and,

FIG. 14 is a bottom view for the design of the implant removal tool of FIG. 8.

Any broken lines shown in the drawings form no part of the claimed design.

**1 Claim, 14 Drawing Sheets**



(58)	<b>Field of Classification Search</b>		4,695,623 A	9/1987	Stabinsky
	CPC .....	A61M 37/0069; A61B 17/3468; A61B 17/3403; A61B 17/221	4,727,138 A	2/1988	Goeddel et al.
	See application file for complete search history.		4,734,284 A	3/1988	Terada et al.
(56)	<b>References Cited</b>		4,737,437 A	4/1988	Gutsell, Jr. et al.
	<b>U.S. PATENT DOCUMENTS</b>		4,743,449 A	5/1988	Yoshida et al.
	2,168,437 A	8/1939 Buercklin	4,753,651 A	6/1988	Eckenhoff
	2,531,724 A	11/1950 Cevasco	4,762,791 A	8/1988	Goeddel et al.
	2,643,653 A	6/1953 Heidrich	4,765,989 A	8/1988	Wong et al.
	D179,537 S	1/1957 Floyd et al.	4,783,337 A	11/1988	Wong et al.
	3,016,895 A	1/1962 Sein	4,818,517 A	4/1989	Kwee et al.
	3,025,991 A	3/1962 Gillon	4,820,267 A	4/1989	Harman
	3,122,162 A	2/1964 Sands	4,820,638 A	4/1989	Swetly et al.
	3,463,157 A *	8/1969 Hunt ..... A61D 1/00 D24/143	4,826,144 A	5/1989	Balsells
	3,523,906 A	8/1970 Vrancken et al.	4,830,344 A	5/1989	Balsells
	3,538,916 A	11/1970 Groff	4,834,708 A	5/1989	Pillari
	3,620,216 A	11/1971 Szymanski	4,845,196 A	7/1989	Cowling
	3,625,214 A	12/1971 Higuchi	4,847,079 A	7/1989	Kwan
	3,632,768 A	1/1972 Bergy et al.	4,851,228 A	7/1989	Zentner et al.
	3,669,104 A	6/1972 Wyatt	4,840,896 A	8/1989	Reddy
	3,691,090 A	9/1972 Kitajima et al.	4,865,845 A	9/1989	Eckenhoff et al.
	D226,915 S	5/1973 Huggins	4,871,094 A	10/1989	Gall et al.
	3,732,865 A	5/1973 Higuchi et al.	4,873,080 A	10/1989	Brickl et al.
	3,737,337 A	6/1973 Sehning et al.	4,874,388 A	10/1989	Wong et al.
	3,766,915 A	10/1973 Rychlik	4,876,781 A	10/1989	Balsells
	3,773,919 A	11/1973 Boswell	4,882,166 A	11/1989	Graham et al.
	3,797,492 A	3/1974 Place	4,885,166 A	12/1989	Meyer et al.
	3,869,549 A	3/1975 Geller	4,886,668 A	12/1989	Haslam et al.
	3,891,570 A	6/1975 Fukushima et al.	4,892,778 A	1/1990	Theeuwes et al.
	D236,035 S	7/1975 Ciencewicki	4,893,795 A	1/1990	Balsells
	3,960,757 A	6/1976 Morishita et al.	4,897,471 A	1/1990	Stabinsky
	3,987,790 A	10/1976 Eckenhoff et al.	4,907,788 A	3/1990	Balsells
	3,995,631 A	12/1976 Higuchi et al.	4,915,366 A	4/1990	Balsells
	3,995,632 A	12/1976 Nakano et al.	4,915,949 A	4/1990	Wong et al.
	4,008,719 A	2/1977 Theeuwes et al.	4,915,954 A	4/1990	Ayer et al.
	4,034,756 A	7/1977 Higuchi et al.	4,917,887 A	4/1990	Hauptmann et al.
	4,078,060 A	3/1978 Benson et al.	4,917,895 A	4/1990	Lee et al.
	4,105,030 A	8/1978 Kercso	4,923,805 A	5/1990	Reddy et al.
	4,111,201 A	9/1978 Theeuwes	4,927,687 A	5/1990	Nuwayser
	4,111,202 A	9/1978 Theeuwes	4,929,554 A	5/1990	Goeddel et al.
	4,111,203 A	9/1978 Theeuwes	4,931,285 A	6/1990	Edgren et al.
	4,203,439 A	5/1980 Theeuwes	4,934,666 A	6/1990	Balsells
	4,211,771 A	7/1980 Witkowski et al.	4,940,465 A	7/1990	Theeuwes et al.
	4,221,862 A	9/1980 Naito et al.	4,940,588 A	7/1990	Sparks et al.
	4,223,674 A	9/1980 Fluent et al.	4,952,402 A	8/1990	Sparks et al.
	4,243,030 A	1/1981 Lynch et al.	4,957,119 A	9/1990	de Nijs
	D258,837 S	4/1981 Spranger et al.	4,961,253 A	10/1990	Balsells
	D259,458 S	6/1981 Fuller et al.	4,964,204 A	10/1990	Balsells
	4,305,927 A	12/1981 Theeuwes et al.	4,969,884 A	11/1990	Yum
	4,310,516 A	1/1982 Chang et al.	4,974,821 A	12/1990	Balsells
	4,340,054 A	7/1982 Michaels	4,976,966 A	12/1990	Theeuwes et al.
	4,350,271 A	9/1982 Eckenhoff	4,994,028 A	2/1991	Leonard et al.
	4,373,527 A	2/1983 Fischell	5,004,689 A	4/1991	Fiers et al.
	4,376,118 A	3/1983 Daher et al.	5,006,346 A	4/1991	Theeuwes et al.
	4,384,975 A	5/1983 Fong	5,019,382 A	5/1991	Cummins, Jr.
	4,389,330 A	6/1983 Tice et al.	5,019,400 A	5/1991	Gombotz et al.
	4,439,196 A	3/1984 Higuchi	5,023,088 A	6/1991	Wong et al.
	4,444,498 A	4/1984 Heinemann	5,024,842 A	6/1991	Edgren et al.
	4,451,253 A	5/1984 Harman	5,030,216 A	7/1991	Theeuwes et al.
	4,455,143 A	6/1984 Theeuwes et al.	5,034,229 A	7/1991	Magruder et al.
	4,455,145 A	6/1984 Theeuwes	5,053,014 A	10/1991	Van Heugten
	4,474,572 A	10/1984 McNaughton et al.	5,056,718 A	10/1991	Wakefield
	4,530,840 A	7/1985 Tice et al.	5,057,318 A	10/1991	Magruder et al.
	4,552,561 A	11/1985 Eckenhoff et al.	5,059,423 A	10/1991	Magruder et al.
	4,588,614 A	5/1986 Lauchenauer	5,066,436 A	11/1991	Komen et al.
	4,594,108 A	6/1986 Greminger, Jr. et al.	5,071,642 A	12/1991	Lahr et al.
	4,597,753 A	7/1986 Turley	5,072,070 A	12/1991	Balsells
	4,609,374 A	9/1986 Ayer	5,079,388 A	1/1992	Balsells
	4,639,244 A	1/1987 Rizk et al.	5,090,962 A	2/1992	Landry et al.
	4,655,462 A	4/1987 Balsells	5,091,188 A	2/1992	Haynes
	4,657,533 A *	4/1987 Oscarsson ..... A61M 37/0069 604/60	5,108,078 A	4/1992	Balsells
	4,673,405 A	6/1987 Guittard et al.	5,110,596 A	5/1992	Magruder et al.
	4,675,184 A	6/1987 Hasegawa et al.	5,112,614 A	5/1992	Magruder et al.
			5,113,938 A	5/1992	Clayton
			5,117,066 A	5/1992	Balsells
			D326,718 S	6/1992	Maxwell
			5,118,666 A	6/1992	Habener
			5,120,306 A	6/1992	Gosselin
			5,120,712 A	6/1992	Habener
			5,120,832 A	6/1992	Goeddel et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,122,128 A	6/1992	Cardinal et al.	5,456,679 A	10/1995	Balaban et al.
5,122,377 A	6/1992	Miller	5,458,888 A	10/1995	Chen
5,126,142 A	6/1992	Ayer et al.	5,464,929 A	11/1995	Bezwada et al.
5,126,147 A	6/1992	Silvestri et al.	5,472,708 A	12/1995	Chen
5,134,244 A	7/1992	Balsells	5,478,564 A	12/1995	Wantier et al.
5,137,727 A	8/1992	Eckenhoff	5,484,403 A	1/1996	Yoakum et al.
D329,278 S	9/1992	Gallup	5,486,365 A	1/1996	Takado et al.
5,147,295 A	9/1992	Stewart	5,498,255 A	3/1996	Wong et al.
5,151,093 A	9/1992	Theeuwes et al.	5,511,355 A	4/1996	Dingler
5,160,122 A	11/1992	Balsells	5,512,293 A	4/1996	Landrau et al.
5,160,743 A	11/1992	Edgren et al.	5,512,549 A	4/1996	Chen et al.
5,161,806 A	11/1992	Balsells	5,514,110 A	5/1996	Teh
5,180,591 A	1/1993	Margruder et al.	5,529,914 A	6/1996	Hubbell et al.
5,190,765 A	3/1993	Jao et al.	5,531,736 A	7/1996	Wong et al.
5,192,273 A	3/1993	Bierman	5,540,665 A	7/1996	Mercado et al.
5,203,849 A	4/1993	Balsells	5,540,912 A	7/1996	Roorda et al.
5,204,108 A	4/1993	Illum	5,541,172 A	7/1996	Labrie et al.
5,207,752 A	5/1993	Sorensen et al.	5,542,682 A	8/1996	Goldstein et al.
5,209,746 A	5/1993	Balaban et al.	5,543,156 A	8/1996	Roorda et al.
5,213,809 A	5/1993	Wright et al.	5,545,618 A	8/1996	Buckley et al.
5,213,810 A	5/1993	Steber	5,556,642 A	9/1996	Kobayashi et al.
5,219,572 A	6/1993	Sivaramakrishnan	5,557,318 A	9/1996	Gabriel
5,221,278 A	6/1993	Linkwitz et al.	5,558,637 A	9/1996	Allonen et al.
5,223,265 A	6/1993	Wong	5,569,289 A	10/1996	Yoon
5,225,205 A	7/1993	Orsolini	5,571,525 A	11/1996	Roorda et al.
5,231,176 A	7/1993	Goeddel et al.	5,574,008 A	11/1996	Johnson et al.
5,234,424 A	8/1993	Yum et al.	5,574,137 A	11/1996	Gray et al.
5,234,692 A	8/1993	Magruder et al.	5,580,578 A	12/1996	Oshlack et al.
5,234,693 A	8/1993	Magruder et al.	5,589,167 A	12/1996	Cleland et al.
5,234,695 A	8/1993	Hobbs et al.	5,595,751 A	1/1997	Bezwada
5,250,026 A	10/1993	Ehrlich et al.	5,595,759 A	1/1997	Wright et al.
5,252,338 A	10/1993	Jao et al.	5,597,579 A	1/1997	Bezwada et al.
5,260,069 A	11/1993	Chen	5,602,010 A	2/1997	Hauptmann et al.
D342,855 S	1/1994	Butler, II	5,605,688 A	2/1997	Himmeler et al.
5,278,151 A	1/1994	Korb et al.	5,607,687 A	3/1997	Bezwada et al.
5,279,544 A	1/1994	Gross et al.	5,609,885 A	3/1997	Rivera et al.
5,279,554 A	1/1994	Turley	5,613,954 A	3/1997	Nelson et al.
5,279,555 A	1/1994	Lifshey	5,614,221 A	3/1997	Fjellstrom
5,279,608 A	1/1994	Cherif Cheikh	5,614,492 A	3/1997	Habener
5,284,655 A	2/1994	Bogdanský et al.	5,618,552 A	4/1997	Bezwada et al.
5,288,501 A	2/1994	Nürnberg et al.	5,620,698 A	4/1997	Bezwada et al.
5,288,502 A	2/1994	McGinity et al.	5,620,705 A	4/1997	Dong et al.
5,290,271 A	3/1994	Jernberg	5,630,796 A	5/1997	Bellhouse et al.
5,300,079 A	4/1994	Niezink et al.	5,633,011 A	5/1997	Dong et al.
5,300,302 A	4/1994	Tachon et al.	5,635,213 A	6/1997	Nystrom et al.
5,308,348 A	5/1994	Balaban et al.	5,639,477 A	6/1997	Maruyama et al.
5,312,335 A	5/1994	McKinnon et al.	5,639,640 A	6/1997	Reddy et al.
5,312,389 A	5/1994	Theeuwes et al.	5,645,850 A	7/1997	Bezwada et al.
5,312,390 A	5/1994	Wong	5,648,088 A	7/1997	Bezwada et al.
5,318,558 A	6/1994	Linkwitz et al.	5,650,173 A	7/1997	Ramstack et al.
5,318,780 A	6/1994	Viegas et al.	5,654,008 A	8/1997	Herbert et al.
5,320,616 A	6/1994	Magndu et al.	5,654,010 A	8/1997	Johnson et al.
5,324,280 A	6/1994	Wong et al.	5,656,297 A	8/1997	Bernstein et al.
5,336,057 A	8/1994	Fukuda et al.	5,656,299 A	8/1997	Kino et al.
5,336,505 A	8/1994	Ng et al.	5,658,593 A	8/1997	Orly et al.
5,348,544 A	9/1994	Sweeney et al.	5,660,847 A	8/1997	Magruder et al.
5,352,662 A	10/1994	Brooks et al.	5,660,858 A	8/1997	Parikh et al.
5,368,588 A	11/1994	Bettinger	5,660,861 A	8/1997	Jao et al.
5,368,863 A	11/1994	Eckenhoff et al.	5,667,808 A	9/1997	Johnson et al.
5,371,089 A	12/1994	Rattan	5,668,170 A	9/1997	Gyory
5,374,620 A	12/1994	Clark et al.	5,672,549 A	9/1997	Minami et al.
5,385,738 A	1/1995	Yamahira et al.	5,676,942 A	10/1997	Testa et al.
5,385,887 A	1/1995	Yim et al.	5,686,097 A	11/1997	Taskovich et al.
5,395,319 A	3/1995	Hirsch et al.	5,688,801 A	11/1997	Mesens et al.
5,407,609 A	4/1995	Tice et al.	5,690,925 A	11/1997	Gray et al.
D358,644 S	5/1995	Park	5,690,952 A	11/1997	Magruder et al.
5,411,951 A	5/1995	Mitchell	5,695,463 A	12/1997	Cherif-Cheikh
5,413,572 A	5/1995	Wong et al.	5,697,113 A	12/1997	Shatz et al.
5,413,672 A	5/1995	Hirotsuji et al.	5,697,914 A	12/1997	Brimhall
5,424,286 A	6/1995	Eng	5,698,213 A	12/1997	Jamiolkowski et al.
5,428,024 A	6/1995	Chu et al.	5,700,486 A	12/1997	Canal et al.
5,429,602 A	7/1995	Hauser	5,700,583 A	12/1997	Jamiolkowski et al.
5,439,688 A	8/1995	Orsolini et al.	5,703,200 A	12/1997	Bezwada et al.
5,443,459 A	8/1995	Wong et al.	5,707,644 A	1/1998	Illum
5,445,829 A	8/1995	Paradissis et al.	5,711,967 A	1/1998	Juch
			5,713,847 A	2/1998	Howard, III et al.
			5,718,922 A	2/1998	Herrero-Vanrell
			5,725,497 A	3/1998	Woodruff et al.
			5,728,088 A	3/1998	Margruder et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

- |             |         |                     |              |         |                      |
|-------------|---------|---------------------|--------------|---------|----------------------|
| 5,728,396 A | 3/1998  | Peery et al.        | D430,671 S   | 9/2000  | Shute                |
| 5,733,572 A | 3/1998  | Unger et al.        | 6,113,938 A  | 9/2000  | Chen et al.          |
| 5,736,159 A | 4/1998  | Chen et al.         | 6,113,947 A  | 9/2000  | Cleland et al.       |
| 5,738,845 A | 4/1998  | Imakawa             | 6,120,787 A  | 9/2000  | Gustafsson et al.    |
| 5,747,058 A | 5/1998  | Tipton et al.       | 6,124,261 A  | 9/2000  | Stevenson et al.     |
| 5,756,450 A | 5/1998  | Hahn et al.         | 6,124,281 A  | 9/2000  | Lewis et al.         |
| 5,767,251 A | 6/1998  | Reddy et al.        | 6,127,520 A  | 10/2000 | Ueda et al.          |
| 5,770,231 A | 6/1998  | Mesens et al.       | 6,129,761 A  | 10/2000 | Hubbell              |
| 5,782,396 A | 7/1998  | Mastri et al.       | 6,130,200 A  | 10/2000 | Brodbeck et al.      |
| 5,792,477 A | 8/1998  | Rickey et al.       | 6,132,420 A  | 10/2000 | Dionne et al.        |
| 5,795,591 A | 8/1998  | Lee et al.          | 6,133,249 A  | 10/2000 | Hills                |
| 5,795,779 A | 8/1998  | McCormick et al.    | 6,133,429 A  | 10/2000 | Davis et al.         |
| 5,807,876 A | 9/1998  | Armistead et al.    | 6,146,139 A  | 11/2000 | Harrison, III        |
| 5,810,769 A | 9/1998  | Schlegel et al.     | 6,147,168 A  | 11/2000 | Jamiolkowski et al.  |
| 5,814,323 A | 9/1998  | Lyle                | 6,156,331 A  | 12/2000 | Peery et al.         |
| D399,821 S  | 10/1998 | Tyneski et al.      | 6,172,046 B1 | 1/2001  | Albrecht             |
| 5,817,129 A | 10/1998 | Labrecque et al.    | 6,174,547 B1 | 1/2001  | Dong et al.          |
| 5,827,297 A | 10/1998 | Boudjema            | 6,177,096 B1 | 1/2001  | Zerbe et al.         |
| 5,830,501 A | 11/1998 | Dong et al.         | 6,183,461 B1 | 2/2001  | Matsuura et al.      |
| 5,836,935 A | 11/1998 | Ashton et al.       | 6,187,095 B1 | 2/2001  | Labrecque et al.     |
| 5,843,891 A | 12/1998 | Sherman             | 6,190,350 B1 | 2/2001  | Davis et al.         |
| 5,844,017 A | 12/1998 | Jamiolkowski et al. | 6,190,700 B1 | 2/2001  | Okada et al.         |
| 5,851,451 A | 12/1998 | Takechi et al.      | 6,190,702 B1 | 2/2001  | Takada et al.        |
| 5,858,746 A | 1/1999  | Hubbell et al.      | 6,191,102 B1 | 2/2001  | DiMarchi et al.      |
| 5,859,150 A | 1/1999  | Jamiolkowski et al. | 6,204,022 B1 | 3/2001  | Johnson et al.       |
| 5,861,166 A | 1/1999  | Eckenhoff           | 6,217,893 B1 | 4/2001  | Pellet et al.        |
| 5,871,770 A | 2/1999  | Margruder et al.    | 6,217,906 B1 | 4/2001  | Gumucio et al.       |
| 5,871,778 A | 2/1999  | Kino et al.         | 6,217,908 B1 | 4/2001  | Mathiowitz et al.    |
| 5,874,388 A | 2/1999  | Hsu                 | 6,218,431 B1 | 4/2001  | Schoen et al.        |
| 5,876,746 A | 3/1999  | Jona et al.         | 6,224,894 B1 | 5/2001  | Jamiolkowski et al.  |
| 5,882,676 A | 3/1999  | Lee et al.          | 6,235,712 B1 | 5/2001  | Stevenson et al.     |
| D408,917 S  | 4/1999  | Hacker              | 6,245,349 B1 | 6/2001  | Yiv et al.           |
| 5,904,935 A | 5/1999  | Eckenhoff et al.    | 6,245,357 B1 | 6/2001  | Edgren et al.        |
| 5,906,599 A | 5/1999  | Kaldany             | 6,248,112 B1 | 6/2001  | Gambale et al.       |
| 5,906,816 A | 5/1999  | Soos et al.         | 6,251,435 B1 | 6/2001  | Jamiolkowski et al.  |
| 5,906,830 A | 5/1999  | Farinas et al.      | D445,975 S   | 7/2001  | Stratford            |
| 5,908,621 A | 6/1999  | Glue et al.         | 6,258,377 B1 | 7/2001  | New et al.           |
| 5,916,598 A | 6/1999  | Rickey et al.       | 6,261,584 B1 | 7/2001  | Peery et al.         |
| 5,922,253 A | 7/1999  | Herbert et al.      | 6,268,343 B1 | 7/2001  | Knudsen et al.       |
| 5,928,666 A | 7/1999  | Farinas et al.      | 6,270,700 B1 | 8/2001  | Ignatious            |
| 5,932,547 A | 8/1999  | Stevenson et al.    | 6,270,787 B1 | 8/2001  | Ayer                 |
| 5,938,654 A | 8/1999  | Wong et al.         | 6,277,413 B1 | 8/2001  | Sankaram             |
| 5,939,286 A | 8/1999  | Johnson et al.      | 6,283,949 B1 | 9/2001  | Roorda               |
| 5,942,223 A | 8/1999  | Bazer et al.        | 6,284,264 B1 | 9/2001  | Zerbe et al.         |
| 5,942,253 A | 8/1999  | Gombotz et al.      | 6,284,725 B1 | 9/2001  | Coolidge et al.      |
| 5,945,126 A | 8/1999  | Thanoo et al.       | 6,284,727 B1 | 9/2001  | Kim et al.           |
| 5,948,430 A | 9/1999  | Zerbe et al.        | 6,287,295 B1 | 9/2001  | Chen et al.          |
| 5,951,521 A | 9/1999  | Mastrototaro et al. | 6,329,336 B1 | 12/2001 | Bridon et al.        |
| 5,958,909 A | 9/1999  | Habener             | 6,331,311 B1 | 12/2001 | Brodbeck et al.      |
| D415,073 S  | 10/1999 | Meehan et al.       | 6,372,218 B1 | 4/2002  | Cummins, Jr.         |
| 5,962,023 A | 10/1999 | Jamiolkowski et al. | 6,372,256 B2 | 4/2002  | Jamiolkowski et al.  |
| 5,965,168 A | 10/1999 | Mesens et al.       | 6,375,978 B1 | 4/2002  | Kleiner et al.       |
| 5,972,370 A | 10/1999 | Eckenhoff et al.    | 6,395,292 B2 | 5/2002  | Peery et al.         |
| 5,972,373 A | 10/1999 | Yajima et al.       | 6,402,716 B1 | 6/2002  | Ryoo                 |
| 5,976,109 A | 11/1999 | Heruth              | 6,403,655 B1 | 6/2002  | Bezwada et al.       |
| 5,980,945 A | 11/1999 | Ruiz                | 6,419,952 B2 | 7/2002  | Wong et al.          |
| 5,981,719 A | 11/1999 | Woiszwillo et al.   | 6,428,517 B1 | 8/2002  | Hochman et al.       |
| 5,984,890 A | 11/1999 | Gast et al.         | 6,433,144 B1 | 8/2002  | Morris et al.        |
| 5,985,305 A | 11/1999 | Peery et al.        | 6,436,091 B1 | 8/2002  | Harper et al.        |
| 5,989,463 A | 11/1999 | Tracy et al.        | 6,447,522 B2 | 9/2002  | Gambale et al.       |
| 5,997,527 A | 12/1999 | Gumucio et al.      | 6,451,974 B1 | 9/2002  | Hansen               |
| 5,997,902 A | 12/1999 | Maruyama et al.     | 6,458,385 B2 | 10/2002 | Jamiolkowski et al.  |
| 6,007,805 A | 12/1999 | Foster et al.       | 6,458,387 B1 | 10/2002 | Scott et al.         |
| 6,017,545 A | 1/2000  | Modi                | 6,458,924 B2 | 10/2002 | Knudsen et al.       |
| 6,022,561 A | 2/2000  | Carlsson et al.     | 6,461,605 B1 | 10/2002 | Cutler et al.        |
| 6,023,802 A | 2/2000  | King                | 6,464,688 B1 | 10/2002 | Harper et al.        |
| 6,029,361 A | 2/2000  | Newman              | 6,468,961 B1 | 10/2002 | Brodbeck et al.      |
| 6,053,927 A | 4/2000  | Hamas               | 6,471,688 B1 | 10/2002 | Harper et al.        |
| 6,060,450 A | 5/2000  | Soos et al.         | 6,472,512 B1 | 10/2002 | LaFleur et al.       |
| 6,069,133 A | 5/2000  | Carlo et al.        | 6,478,768 B1 | 11/2002 | Kneer                |
| 6,074,377 A | 6/2000  | Sanfilippo, II      | 6,485,706 B1 | 11/2002 | McCoy et al.         |
| 6,074,660 A | 6/2000  | Jamiolkowski et al. | 6,495,164 B1 | 12/2002 | Ramstack et al.      |
| 6,074,673 A | 6/2000  | Guillen             | 6,506,724 B1 | 1/2003  | Hiles et al.         |
| 6,100,346 A | 8/2000  | Jamiolkowski et al. | 6,508,808 B1 | 1/2003  | Carr et al.          |
| 6,110,503 A | 8/2000  | Rickey et al.       | 6,514,500 B1 | 2/2003  | Bridon et al.        |
|             |         |                     | 6,514,517 B2 | 2/2003  | Jamilolkowski et al. |
|             |         |                     | 6,524,305 B1 | 2/2003  | Peterson et al.      |
|             |         |                     | 6,528,093 B1 | 3/2003  | Kamei et al.         |
|             |         |                     | 6,528,486 B1 | 3/2003  | Larsen et al.        |

(56)

**References Cited**

**U.S. PATENT DOCUMENTS**

D472,896 S	4/2003	Peiker	7,205,409 B2	4/2007	Pei et al.
6,541,021 B1	4/2003	Johnson et al.	7,207,982 B2	4/2007	Dionne et al.
6,544,239 B2	4/2003	Kinsey et al.	7,214,206 B2	5/2007	Rue et al.
6,544,252 B1	4/2003	Theeuwes et al.	7,241,457 B2	7/2007	Chen et al.
6,547,250 B1	4/2003	Noble	7,258,869 B1	8/2007	Berry et al.
6,551,613 B1	4/2003	Dong et al.	D555,589 S	11/2007	Hussaini et al.
6,569,420 B2	5/2003	Chen et al.	7,297,761 B2	11/2007	Beeley et al.
6,572,890 B2	6/2003	Faour et al.	7,316,680 B2	1/2008	Gilbert
6,579,851 B2	6/2003	Goeke et al.	7,393,827 B2	7/2008	Nadler
6,589,157 B2	7/2003	Fontayne et al.	7,407,499 B2	8/2008	Trautman
6,592,508 B1	7/2003	Ravins et al.	7,442,682 B2	10/2008	Kitaura et al.
6,592,887 B2	7/2003	Zerbe et al.	7,456,254 B2	11/2008	Wright et al.
6,593,295 B2	7/2003	Bridon et al.	7,459,432 B2	12/2008	Cowley et al.
6,607,529 B1	8/2003	Jones et al.	7,521,423 B2	4/2009	Young et al.
6,626,863 B1	9/2003	Berler	7,563,871 B2	7/2009	Wright et al.
6,635,268 B2	10/2003	Peery et al.	7,589,169 B2	9/2009	Bolotin
6,645,192 B2	11/2003	Kenison	7,604,647 B2	10/2009	Chen
6,667,061 B2	12/2003	Ramstack et al.	7,612,176 B2	11/2009	Wright et al.
6,670,368 B1	12/2003	Breault et al.	7,632,256 B2	12/2009	Mosler et al.
6,673,767 B1	1/2004	Brodbeck et al.	7,635,463 B2	12/2009	Bolotin et al.
6,682,522 B2	1/2004	Carr et al.	D608,447 S	1/2010	Meyer et al.
6,703,225 B1	3/2004	Kojima et al.	7,655,254 B2	2/2010	Dennis et al.
6,703,359 B1	3/2004	Young et al.	7,655,257 B2	2/2010	Peery et al.
6,706,689 B2	3/2004	Coolidge et al.	7,666,835 B2	2/2010	Bloom et al.
6,709,671 B2	3/2004	Zerbe et al.	7,682,356 B2	3/2010	Alessi et al.
6,720,407 B1	4/2004	Hughes et al.	7,727,519 B2	6/2010	Moran
6,730,328 B2	5/2004	Maskiwicz et al.	7,731,947 B2	6/2010	Eliaz et al.
6,752,753 B1	6/2004	Hoskins et al.	7,736,665 B2	6/2010	Patel et al.
D492,995 S *	7/2004	Rue ..... D24/133	7,741,269 B2	6/2010	Young et al.
6,767,887 B1	7/2004	Hoffmann et al.	7,766,924 B1	8/2010	Bombard et al.
6,821,949 B2	11/2004	Bridon et al.	7,790,140 B2	9/2010	Bolotin
6,833,256 B1	12/2004	Pontzer et al.	7,825,091 B2	11/2010	Bloom et al.
6,835,194 B2	12/2004	Johnson et al.	7,829,109 B2	11/2010	Chen et al.
6,840,931 B2	1/2005	Peterson et al.	7,833,543 B2	11/2010	Gibson et al.
6,849,708 B1	2/2005	Habener	7,879,028 B2	2/2011	Alessi et al.
6,849,714 B1	2/2005	Bridon et al.	7,879,794 B2	4/2011	Weyer et al.
6,858,576 B1	2/2005	Young et al.	7,919,109 B2	4/2011	Berry et al.
6,872,700 B1	3/2005	Young et al.	7,928,065 B2	4/2011	Young et al.
6,875,748 B2	4/2005	Manthorpe et al.	D638,478 S	5/2011	Block
6,887,470 B1	5/2005	Bridon et al.	7,959,938 B2	6/2011	Rohloff et al.
6,887,849 B2	5/2005	Bridon et al.	7,964,183 B2	6/2011	Eliaz et al.
6,899,887 B2	5/2005	Ayer	8,039,432 B2	10/2011	Bridon et al.
6,899,898 B2	5/2005	Albayrak	8,048,438 B2	11/2011	Berry et al.
6,902,744 B1	6/2005	Kolterman et al.	8,052,996 B2	11/2011	Lautenbach et al.
6,903,186 B1	6/2005	Dong	8,058,233 B2	11/2011	Cowley et al.
6,913,767 B1	7/2005	Cleland et al.	8,101,576 B2	1/2012	Bloom
6,923,800 B2	8/2005	Chen et al.	8,114,430 B2	2/2012	Rohloff et al.
6,924,264 B1	8/2005	Prickett et al.	8,114,437 B2	2/2012	Rohloff et al.
6,939,556 B2	9/2005	Lautenbach	8,158,150 B2	4/2012	Lautenbach et al.
6,956,026 B2	10/2005	Beeley et al.	8,173,150 B2	5/2012	Berry et al.
6,960,192 B1	11/2005	Flaherty et al.	8,190,702 B1	5/2012	Sakata et al.
6,969,702 B2	11/2005	Bertilsson et al.	8,202,836 B2	6/2012	Moore et al.
6,976,981 B2	12/2005	Ayer	8,206,745 B2	6/2012	Rohloff et al.
6,989,366 B2	1/2006	Beeley et al.	8,211,467 B2	7/2012	Rohloff et al.
6,992,065 B2	1/2006	Okumu	8,217,001 B2	7/2012	Cowley et al.
6,997,922 B2	2/2006	Theeuwes et al.	8,231,859 B2	7/2012	Bolotin et al.
7,008,439 B1	3/2006	Janzen et al.	8,251,946 B2	8/2012	Bardy
7,014,636 B2	3/2006	Gilbert	8,257,682 B2	9/2012	Bolotin et al.
7,022,674 B2	4/2006	DeFelippis et al.	8,257,691 B2	9/2012	Eliaz et al.
7,041,646 B2	5/2006	Pan et al.	8,262,667 B1	9/2012	Silver et al.
7,074,423 B2	7/2006	Fereira et al.	8,263,545 B2	9/2012	Levy et al.
7,084,243 B2	8/2006	Glaesner et al.	8,263,736 B2	9/2012	Berry
7,101,567 B1	9/2006	Sano et al.	8,268,341 B2	9/2012	Berry et al.
7,101,843 B2	9/2006	Glaesner et al.	8,273,365 B2	9/2012	Lautenbach et al.
7,112,335 B2	9/2006	Lautenbach	8,273,713 B2	9/2012	Pittner et al.
7,115,569 B2	10/2006	Beeley et al.	D669,589 S	10/2012	Delaey
7,138,375 B2	11/2006	Beeley et al.	8,277,776 B2	10/2012	Bolotin et al.
7,138,486 B2	11/2006	Habener et al.	8,278,267 B2	10/2012	Weyer et al.
7,141,547 B2	11/2006	Rosen et al.	8,288,338 B2	10/2012	Young et al.
7,144,863 B2	12/2006	DeFelippis et al.	8,298,561 B2	10/2012	Alessi et al.
7,153,825 B2	12/2006	Young et al.	8,299,025 B2	10/2012	Alessi et al.
7,157,555 B1	1/2007	Beeley et al.	8,343,140 B2	1/2013	Alessi et al.
7,163,688 B2	1/2007	Peery et al.	8,367,095 B2	2/2013	Lautenbach et al.
7,163,697 B2	1/2007	Hanes et al.	8,372,424 B2	2/2013	Berry et al.
7,199,217 B2	4/2007	DiMarchi et al.	D678,889 S	3/2013	Chiu
			8,398,967 B2	3/2013	Eliaz et al.
			8,440,226 B2	5/2013	Rohloff et al.
			8,454,552 B2	6/2013	Bardy
			8,460,694 B2	6/2013	Rohloff et al.

(56)

**References Cited**

## U.S. PATENT DOCUMENTS

8,470,353 B2	6/2013	Lautenbach et al.
8,722,037 B2	5/2014	Veenstra et al.
8,747,412 B2	6/2014	Bae et al.
8,801,700 B2	8/2014	Alessi et al.
8,815,802 B2	8/2014	Kalthoff et al.
8,858,621 B2	10/2014	Oba et al.
8,865,202 B2	10/2014	Zerbe et al.
8,888,745 B2	11/2014	Van Der Graaf et al.
8,926,595 B2	1/2015	Alessi et al.
8,940,316 B2	1/2015	Alessi et al.
8,992,961 B2	3/2015	Berry et al.
8,992,962 B2	3/2015	Lautenbach et al.
9,044,209 B2	6/2015	Dayton et al.
9,078,900 B2	7/2015	Kuzma et al.
9,095,553 B2	8/2015	Rohloff et al.
9,241,722 B2	1/2016	Yu
D750,764 S	3/2016	DeSocio
9,332,995 B2	5/2016	Russo
9,526,763 B2	12/2016	Rohloff et al.
9,539,200 B2	1/2017	Lautenbach
9,572,889 B2	2/2017	Alessi et al.
D789,539 S	6/2017	Kleiner et al.
D789,540 S	6/2017	Gyorgy
9,682,127 B2	6/2017	Alessi et al.
RE46,577 E	10/2017	Collins et al.
9,889,085 B1	2/2018	Alessi et al.
2001/0012511 A1	8/2001	Bezwada et al.
2001/0021377 A1	9/2001	Jamiolkowski et al.
2001/0021822 A1	9/2001	Ayer
2001/0022974 A1	9/2001	Ayer
2001/0026793 A1	10/2001	Jamiolkowski et al.
2001/0027311 A1	10/2001	Chen et al.
2001/0031940 A1	10/2001	Loos
2001/0031790 A1	11/2001	Beisswenger
2001/0036472 A1	11/2001	Wong et al.
2001/0040326 A1	11/2001	Balczun
2002/0001631 A1	1/2002	Okumu
2002/0004481 A1	1/2002	Cleland et al.
2002/0012818 A1	1/2002	Ruppi et al.
2002/0034532 A1	3/2002	Brodbeck et al.
2002/0037309 A1	3/2002	Jaworowicz et al.
2002/0048600 A1	4/2002	Bhatt et al.
2002/0077599 A1	6/2002	Wojcik
2002/0098180 A1	7/2002	Lei
2002/0136848 A1	9/2002	Yoshii et al.
2002/0137666 A1	9/2002	Beeley et al.
2002/0141985 A1	10/2002	Pittner et al.
2002/0197185 A1	12/2002	Jamiolkowski et al.
2002/0197235 A1	12/2002	Moran
2003/0007992 A1	1/2003	Gibson et al.
2003/0032947 A1	2/2003	Harper et al.
2003/0040699 A1	2/2003	Talling et al.
2003/0044467 A1	3/2003	Brodbeck et al.
2003/0045454 A1	3/2003	Okumu et al.
2003/0059376 A1	3/2003	Libbey et al.
2003/0059471 A1	3/2003	Compton et al.
2003/0060425 A1	3/2003	Ahlem et al.
2003/0078616 A1	4/2003	Fey et al.
2003/0078618 A1	4/2003	Fey et al.
2003/0097121 A1	5/2003	Jolly et al.
2003/0104063 A1	6/2003	Babcock et al.
2003/0108608 A1	6/2003	Laridon et al.
2003/0108609 A1	6/2003	Berry et al.
2003/0113380 A1	6/2003	Ramstack et al.
2003/0114837 A1	6/2003	Peterson et al.
2003/0118660 A1	6/2003	Rickey et al.
2003/0135153 A1	7/2003	Hagemeyer
2003/0138403 A1	7/2003	Drustrup
2003/0138491 A1	7/2003	Tracy et al.
2003/0157178 A1	8/2003	Chen et al.
2003/0170289 A1	9/2003	Chen et al.
2003/0180364 A1	9/2003	Chen et al.
2003/0186858 A1	10/2003	Arentsen
2003/0191099 A1	10/2003	Bohlmann et al.
2003/0211974 A1	11/2003	Brodbeck et al.
2003/0215515 A1	11/2003	Truong-Le et al.
2003/0220617 A1	11/2003	Dickerson
2003/0233101 A1	12/2003	Lubbock et al.
2004/0001689 A1	1/2004	Goldsmith et al.
2004/0001889 A1	1/2004	Chen et al.
2004/0002442 A1	1/2004	Pan et al.
2004/0022859 A1	2/2004	Chen et al.
2004/0024068 A1	2/2004	Levy et al.
2004/0024069 A1	2/2004	Chen et al.
2004/0029784 A1	2/2004	Hathaway
2004/0039376 A1	2/2004	Peery et al.
2004/0047888 A1	3/2004	Kenison et al.
2004/0097906 A1	5/2004	Fereira et al.
2004/0101557 A1	5/2004	Gibson et al.
2004/0102762 A1	5/2004	Gilbert
2004/0115236 A1	6/2004	Chan et al.
2004/0142867 A1	7/2004	Oi et al.
2004/0142902 A1	7/2004	Struijker-Boudier
2004/0151753 A1	8/2004	Chen et al.
2004/0157951 A1	8/2004	Wolf
2004/0198654 A1	10/2004	Glaesner et al.
2004/0199140 A1	10/2004	Rue et al.
2004/0209801 A1	10/2004	Brand et al.
2004/0215133 A1	10/2004	Weber et al.
2004/0224903 A1	11/2004	Berry et al.
2004/0225113 A1	11/2004	LaFleur et al.
2004/0243106 A1	12/2004	Ayer
2004/0265273 A1	12/2004	Li et al.
2004/0266683 A1	12/2004	Hathaway et al.
2004/0266692 A1	12/2004	Young et al.
2005/0004557 A1	1/2005	Russell
2005/0008661 A1	1/2005	Fereira et al.
2005/0009742 A1	1/2005	Bertilsson et al.
2005/0010196 A1	1/2005	Fereira et al.
2005/0010942 A1	1/2005	Kim et al.
2005/0070883 A1	3/2005	Brown et al.
2005/0070927 A1	3/2005	Feinberg
2005/0079200 A1	4/2005	Rathenow et al.
2005/0079202 A1	4/2005	Chen et al.
2005/0095284 A1	5/2005	Trautman
2005/0101943 A1	5/2005	Ayer et al.
2005/0106214 A1	5/2005	Chen
2005/0112188 A1	5/2005	Eliaz et al.
2005/0118206 A1	6/2005	Luk et al.
2005/0118221 A1	6/2005	Blakely et al.
2005/0131386 A1	6/2005	Freeman et al.
2005/0131389 A1	6/2005	Peterson et al.
2005/0143749 A1	6/2005	Zalenski et al.
2005/0175701 A1	8/2005	Pan et al.
2005/0201980 A1	9/2005	Moran
2005/0215475 A1	9/2005	Ong et al.
2005/0216087 A1	9/2005	Zucherman et al.
2005/0266087 A1	12/2005	Junnarkar et al.
2005/0271702 A1	12/2005	Wright et al.
2005/0276856 A1	12/2005	Fereira et al.
2005/0281879 A1	12/2005	Chen et al.
2006/0013879 A9	1/2006	Brodbeck et al.
2006/0014678 A1	1/2006	Cowley et al.
2006/0030526 A1	2/2006	Liu et al.
2006/0069029 A1	3/2006	Kolterman et al.
2006/0073182 A1	4/2006	Wong et al.
2006/0084604 A1	4/2006	Kitaura et al.
2006/0084922 A1	4/2006	Botha
2006/0094652 A1	5/2006	Levy et al.
2006/0094693 A1	5/2006	Aziz et al.
2006/0106399 A1	5/2006	Taras et al.
2006/0141040 A1	6/2006	Chen et al.
2006/0142234 A1	6/2006	Chen et al.
2006/0160736 A1	7/2006	Nadler
2006/0178304 A1	8/2006	Juul-Mortensen et al.
2006/0193918 A1	8/2006	Rohloff et al.
2006/0216242 A1	9/2006	Rohloff et al.
2006/0224145 A1	10/2006	Gills
2006/0233841 A1	10/2006	Brodbeck et al.
2006/0246138 A1	11/2006	Rohloff et al.
2006/0251618 A1	11/2006	Dennis et al.
2006/0263433 A1	11/2006	Ayer et al.
2006/0264890 A1	11/2006	Moberg et al.
2006/0280795 A1	12/2006	Penhasi et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2006/0293232 A1 12/2006 Levy et al.  
 2007/0027105 A1 2/2007 Junnarkar et al.  
 2007/0141102 A1 6/2007 De Graaff et al.  
 2007/0149011 A1 6/2007 Kent et al.  
 2007/0166352 A1 7/2007 Wright et al.  
 2007/0248572 A1 10/2007 Moran et al.  
 2007/0281024 A1 12/2007 Lautenbach et al.  
 2008/0020016 A1 1/2008 Li et al.  
 2008/0038316 A1 2/2008 Wong et al.  
 2008/0064636 A1 3/2008 Bloom et al.  
 2008/0065090 A1 3/2008 Scribner et al.  
 2008/0091176 A1 4/2008 Alessi  
 2008/0110515 A1 5/2008 Angelosanto et al.  
 2008/0112994 A1 5/2008 Junnarkar et al.  
 2008/0200383 A1 8/2008 Jennings et al.  
 2008/0207512 A1 8/2008 Roth et al.  
 2008/0208194 A1 8/2008 Bickenbach  
 2008/0226625 A1 9/2008 Berry  
 2008/0226689 A1 9/2008 Betty et al.  
 2008/0260838 A1 10/2008 Hokenson et al.  
 2008/0260840 A1 10/2008 Alessi et al.  
 2008/0269725 A1 10/2008 Deem et al.  
 2008/0312157 A1 12/2008 Levy et al.  
 2009/0012463 A1 1/2009 Beelen et al.  
 2009/0022727 A1 1/2009 Houston et al.  
 2009/0036364 A1 2/2009 Levy et al.  
 2009/0042781 A1 2/2009 Petersen et al.  
 2009/0074734 A1 3/2009 Rottiers  
 2009/0087408 A1 4/2009 Berry et al.  
 2009/0156474 A1 6/2009 Roth et al.  
 2009/0163447 A1 6/2009 Maggio  
 2009/0186817 A1 7/2009 Ghosh et al.  
 2009/0202481 A1 8/2009 Li et al.  
 2009/0202608 A1 8/2009 Alessi et al.  
 2009/0209460 A1 8/2009 Young et al.  
 2009/0210019 A1 8/2009 Kim et al.  
 2009/0215694 A1 8/2009 Kolterman et al.  
 2009/0234392 A1 9/2009 Dziejczak  
 2009/0247463 A1 10/2009 Wright et al.  
 2009/0254143 A1 10/2009 Tweden et al.  
 2009/0286723 A1 11/2009 Levy et al.  
 2009/0312246 A1 12/2009 Baron et al.  
 2010/0092566 A1 4/2010 Alessi et al.  
 2010/0094252 A1 4/2010 Wengreen et al.  
 2010/0105627 A1 4/2010 Salama et al.  
 2010/0144621 A1 6/2010 Kim et al.  
 2010/0185184 A1 7/2010 Alessi et al.  
 2010/0297209 A1 11/2010 Rohloff et al.  
 2010/0298807 A1 11/2010 Jansen et al.  
 2010/0298840 A1 11/2010 Schwartz  
 2010/0331868 A1 12/2010 Bardy  
 2010/0331878 A1\* 12/2010 Kleinwachter .... A61B 17/3468  
 606/205  
 2011/0076317 A1 3/2011 Alessi et al.  
 2011/0091527 A1 4/2011 Moonen et al.  
 2011/0104111 A1 5/2011 Rohloff et al.  
 2011/0152181 A1 6/2011 Alsina-Fernandez et al.  
 2011/0152182 A1 6/2011 Alsina-Fernandez et al.  
 2011/0160708 A1 6/2011 Berry et al.  
 2011/0166554 A1 7/2011 Alessi et al.  
 2011/0264077 A1 10/2011 Rohloff et al.  
 2011/0306549 A1 12/2011 Tatarkiewicz et al.  
 2012/0208755 A1 8/2012 Leung  
 2012/0303045 A1 11/2012 Cooper et al.  
 2013/0030417 A1 1/2013 Alessi  
 2013/0034210 A1 2/2013 Rohloff et al.  
 2013/0052237 A1 2/2013 Eliaz et al.  
 2013/0296661 A1 11/2013 Bornzin et al.  
 2013/0324977 A1 12/2013 Vanderpool  
 2014/0058409 A1 2/2014 Bratlie  
 2014/0058425 A1 2/2014 Porat  
 2014/0121741 A1 5/2014 Bennett et al.  
 2014/0163057 A1 6/2014 Patel et al.  
 2014/0236162 A1 8/2014 Barongan  
 2014/0257272 A1 9/2014 Clark, III et al.

2014/0324067 A1 10/2014 Emken et al.  
 2014/0378900 A1 12/2014 Alessi et al.  
 2015/0001118 A1 1/2015 Selepack et al.  
 2015/0057227 A1 2/2015 Leung  
 2015/0133791 A1 5/2015 Sato et al.  
 2015/0231062 A1 8/2015 Lautenbach et al.  
 2015/0231256 A1 8/2015 Berry et al.  
 2015/0297509 A1 10/2015 Schwarz  
 2015/0359553 A1 12/2015 Harnisch  
 2016/0022582 A1 1/2016 Alessi et al.  
 2016/0030337 A1 2/2016 Kuzma et al.  
 2016/0158577 A1\* 6/2016 Escarguel ..... A61M 37/0069  
 600/1  
 2016/0354115 A1 12/2016 Smith et al.  
 2016/0354305 A1 12/2016 Alessi et al.  
 2017/0056476 A1 3/2017 Rohloff et al.  
 2017/0079906 A1 3/2017 Alessi et al.  
 2017/0119854 A1 5/2017 Alessi et al.  
 2017/0119855 A1 5/2017 Berry et al.  
 2017/0181964 A1 6/2017 Lautenbach et al.  
 2017/0252409 A1 9/2017 Leung  
 2017/0273706 A1 9/2017 Mirza et al.  
 2017/0319470 A1 11/2017 Eliaz et al.  
 2017/0319662 A1 11/2017 Berry et al.  
 2017/0348392 A1 12/2017 Rohloff  
 2017/0368145 A1 12/2017 Alessi et al.  
 2018/0009871 A1 1/2018 Blackwell et al.  
 2018/0185451 A1 7/2018 Young et al.  
 2018/0368875 A1\* 12/2018 Castillo ..... A61B 17/3468

FOREIGN PATENT DOCUMENTS

EP 0254394 1/1988  
 EP 0295411 12/1988  
 EP 0304107 A1 2/1989  
 EP 0368339 5/1990  
 EP 0373867 6/1990  
 EP 0431942 6/1991  
 EP 0486959 A1 5/1992  
 EP 0497575 A1 8/1992  
 EP 0521586 A1 1/1993  
 EP 0596161 A1 5/1994  
 EP 0379147 9/1994  
 EP 0627231 12/1994  
 EP 0631794 A1 1/1995  
 EP 0729747 5/1997  
 EP 0771817 5/1997  
 EP 0596161 B1 2/1998  
 EP 0841359 5/1998  
 EP 0767689 6/1999  
 EP 1046399 10/2000  
 EP 1084703 3/2001  
 EP 1300129 A2 4/2003  
 EP 1300173 A2 4/2003  
 EP 1300129 A3 5/2003  
 EP 1323450 A1 7/2003  
 EP 1600187 1/2009  
 EP 2133073 A1 12/2009  
 EP 2020990 9/2010  
 FR 640907 7/1928  
 FR 2616665 A2 12/1988  
 GB 1049104 11/1966  
 GB 1518683 7/1978  
 GB 2138298 B 11/1986  
 GB 2501400 10/2013  
 GB 2501400 A 10/2013  
 JP H02124814 A 5/1990  
 JP H07196479 A 8/1995  
 JP 09-509346 A 9/1997  
 JP 1997/509346 9/1997  
 JP 9241153 9/1997  
 JP 2006/213727 A 8/2006  
 NL 8901004 A 11/1990  
 NL 9000948 A 11/1990  
 NL 9100160 8/1992  
 NL 9100160 A 8/1992  
 NZ 592113 8/2012  
 TW 200634060 10/2006  
 WO WO1989003678 A1 5/1989

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO	WO1990013285	A1	11/1990	WO	WO 00/045790		8/2000
WO	WO1990013361	A1	11/1990	WO	WO 00/054745		9/2000
WO	WO1990013780	A1	11/1990	WO	WO2000059476	A1	10/2000
WO	WO 91/07160		5/1991	WO	WO 00/066138		11/2000
WO	WO1992019241	A1	11/1992	WO	WO 00/067728		11/2000
WO	WO 93/06819		4/1993	WO	WO2000066087	A2	11/2000
WO	WO 93/06821		4/1993	WO	WO2001019345	A1	3/2001
WO	WO 93/008832		5/1993	WO	WO 01/28631	A1	4/2001
WO	WO 93/09763		5/1993	WO	WO2001028525	A2	4/2001
WO	WO 93/23083		11/1993	WO	WO 01/043528		6/2001
WO	WO 94/09743		5/1994	WO	WO 01/051041		7/2001
WO	WO1994010982	A1	5/1994	WO	WO 01/68168	A1	9/2001
WO	WO 94/21262		9/1994	WO	WO 01/78683		10/2001
WO	WO 95/01167		1/1995	WO	WO 02/028366		4/2002
WO	WO 95/09006		4/1995	WO	WO 02/036072		5/2002
WO	WO 95/09007		4/1995	WO	WO 02/043800		6/2002
WO	WO1995013799	A1	5/1995	WO	WO 02/045752		6/2002
WO	WO 95/34285		12/1995	WO	WO 02/47716		6/2002
WO	WO 96/001134		1/1996	WO	WO 02/067895		9/2002
WO	WO 96/003116		2/1996	WO	WO 02/069983		9/2002
WO	WO1996036317	A1	11/1996	WO	02083216	A1	10/2002
WO	WO 96/39142		12/1996	WO	WO 02/76344		10/2002
WO	WO 96/40049		12/1996	WO	WO 02/085428		10/2002
WO	WO 96/40139		12/1996	WO	WO 03/000230		1/2003
WO	WO 96/40355		12/1996	WO	WO 03/007981		1/2003
WO	WO1996040049	A1	12/1996	WO	WO 03/011892		2/2003
WO	WO 97/15289		5/1997	WO	WO 03/024357		3/2003
WO	WO 97/15296		5/1997	WO	WO 03/024503		3/2003
WO	WO 97/28181		8/1997	WO	WO2003020245	A1	3/2003
WO	WO1997031943	A1	9/1997	WO	WO 03/030923		4/2003
WO	WO1997044039	A1	11/1997	WO	WO 03/041684		5/2003
WO	WO 97/46204		12/1997	WO	WO 03/041757		5/2003
WO	WO 97/47339		12/1997	WO	WO 03/053400		7/2003
WO	WO 98/00152		1/1998	WO	WO2003066585	A2	8/2003
WO	WO 98/00157		1/1998	WO	WO 03/072113		9/2003
WO	WO 98/00158		1/1998	WO	WO 03/072133		9/2003
WO	WO 98/02169		1/1998	WO	WO 04/002565		1/2004
WO	WO1997041837	A3	2/1998	WO	WO 2004/026106	A2	4/2004
WO	WO1998007412	A1	2/1998	WO	WO2004034975	A2	4/2004
WO	9813092	A1	4/1998	WO	WO2004035754	A2	4/2004
WO	WO 98/13092	A1	4/1998	WO	WO2004035762	A2	4/2004
WO	WO 98/16250		4/1998	WO	WO2004036186	A2	4/2004
WO	WO 98/17315		4/1998	WO	WO 04/052336		6/2004
WO	WO 1998/13091		4/1998	WO	WO 04/056338		7/2004
WO	WO 98/20930		5/1998	WO	WO 04/089335		10/2004
WO	WO 98/27960		7/1998	WO	WO 2004/089458	A1	10/2004
WO	WO 98/027962		7/1998	WO	WO2004103342	A2	12/2004
WO	WO 98/27963		7/1998	WO	WO 05/048930		6/2005
WO	WO 98/030231		7/1998	WO	WO 05/048952		6/2005
WO	WO 98/32463		7/1998	WO	WO 05/102293		11/2005
WO	WO1998030231	A1	7/1998	WO	WO2005102293	A1	11/2005
WO	WO 98/42317		10/1998	WO	WO2005110425		11/2005
WO	WO 98/47487		10/1998	WO	WO 06/017772		2/2006
WO	WO 98/51282		11/1998	WO	WO 06/023526		3/2006
WO	WO 98/58698	A1	12/1998	WO	WO 2006/077242	A1	7/2006
WO	WO 99/03453		1/1999	WO	WO 2006/077250	A1	7/2006
WO	WO 99/04767		2/1999	WO	WO 06/081279		8/2006
WO	WO 99/004768		2/1999	WO	WO 06/083761		8/2006
WO	WO1999012549	A2	3/1999	WO	WO 06/084139		8/2006
WO	WO 99/16419		4/1999	WO	WO 06/086727		8/2006
WO	WO 99/025728		5/1999	WO	WO 06/101815		9/2006
WO	WO 99/29306		6/1999	WO	WO 06/111169		10/2006
WO	WO 99/033446		7/1999	WO	WO2006/131730		12/2006
WO	WO 99/33449		7/1999	WO	WO 07/024700		3/2007
WO	WO 99/39700		8/1999	WO	WO 07/056681		5/2007
WO	WO 99/040788		8/1999	WO	WO 07/075534		7/2007
WO	WO 99/04659		9/1999	WO	WO 07/084460		7/2007
WO	WO 99/062501		12/1999	WO	WO 2007/082889	A1	7/2007
WO	WO 99/064061		12/1999	WO	WO 07/133778		11/2007
WO	WO 00/013663		3/2000	WO	WO 07/140416		12/2007
WO	WO 00/029206		5/2000	WO	WO 08/021133		2/2008
WO	WO 00/038652		7/2000	WO	WO2008041245	A2	4/2008
WO	WO 00/039280		7/2000	WO	WO 08/061355		5/2008
WO	WO 00/040273		7/2000	WO	WO2008/086086	A2	7/2008
WO	WO 00/041548		7/2000	WO	WO 08/133908		11/2008
				WO	WO 08/134425		11/2008
				WO	WO 09/109927		9/2009
				WO	WO2009143265	A2	11/2009
				WO	WO2009143285	A2	11/2009



(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO	WO 2010/045169	A1	4/2010
WO	2011011697	A1	1/2011
WO	WO 2013/004983	A1	1/2013
WO	2013160347	A1	10/2013
WO	WO 2013/184235	A1	12/2013

## OTHER PUBLICATIONS

Glumetza Brochure 2009, 13 Pages.

Erowid, "Introduction to the Federal Controlled Substance Analog Act" 2001, 4 pages.

Li et al. ("Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" in *Current Therapeutic Research*, vol. 71, No. 4, Aug. 2010.

Nexplanon Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.

International Search Report and Written Opinion for PCT Application No. PCT/US2016/035602 dated Nov. 29, 2016.

Akers, et al., "Formulation Design and Development of Parenteral Suspensions," *Journal of Parenteral Science & Technology*, 41(3): 88-96 (1987).

Alonso, et al., "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," *Pharmaceutical Research*, 10(7):945-953 (1993).

Beck, et al., "Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive," *Biology of Reproduction*, 28(1): 186-195 (1983).

Bodmeier and McGinity, "Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method," *International Journal of Pharmaceutics*, 43(1-2): 179-186 (Apr. 1988).

Cha and Pitt, "A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules," *Journal of Controlled Release*, 7: 69-78 (1988).

Cha and Pitt, "The acceleration of degradation-controlled drug delivery from polyester microspheres," *Journal of Controlled Release*, 8: 259-265 (1989).

Cohen, et al., "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," *Pharmaceutical Research*, 8(6): 713-720 (1991).

Conti, et al., "Use of polylactic acid for the preparation of microparticulate drug delivery systems," *Journal of Microencapsulation*, 9(2): 153-166 (1992).

Hodgman, et al., Eds., *Handbook of Chemistry and Physics*, 35th Edition, 1024-1025 (1953).

Jalil and Nixon, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties," *Journal of Microencapsulation*, 7(3): 297-325 (Jul.-Sep. 1990).

Lee and Timasheff, "The stabilization of proteins by sucrose," *J. Biological Chem.*, 256(14): 7193-7201 (Jul. 1981).

Li, et al., "Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method," *Journal of Controlled Release*, 37: 199-214 (1995).

Maa and Hsu, "Liquid-liquid emulsification by static mixers for use in microencapsulation," *Journal of Microencapsulation*, 13(4): 419-433 (Jul.-Aug. 1996).

Maulding, et al., "Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament," *Journal of Controlled Release*, 3: 103-117 (1986).

Mehta, et al., "Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide)," *Journal of Controlled Release*, 41: 249-257 (1996).

Sah, et al., "A novel method of preparing PLGA microcapsules utilizing methylethyl ketone," *Pharmaceutical Research*, 13(3): 360-367 (1996).

Sato, et al., "Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques," *Pharmaceutical Research*, 5(1): 21-30 (1988).

Szayna, et al., "Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats," *Endocrinology*, 141(6): 1936-1941 (2000).

Thomassin, et al., "A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation," *Eur. J. Pharm. Biopharm.*, 42(1): 16-24 (1996).

van Santbrink and Fauser, "Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens," *J. Clin. Endocrin. Metab.*, 82(11): 3597-3602 (1997).

Tracy et al., "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro," *Biomaterials*. 20(11): 1057-1062 (1999).

Ertl et al., "Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines," *Vaccine* 14(9):879-885.(1996).

Thompson et al., "Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone," *Journal of Controlled Release* 43(1):9-22 (1997).

Bray, "Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin," (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).

"Implantable infusion pumps: technology poised for takeoff," *BBI Newsletter* 17(12):209-211 (Dec. 1994).

Adamson et al., "Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer," *J. Clin. Oncol.* 15(11):3330-3337 (Nov. 1997).

Adolf et al., "Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN)  $\omega$ 1: evidence that IFN- $\omega$ 1 is a component of human leukocyte IFN," *Virology* 175(2):410-471 (Apr. 1990).

Adolf et al., "Antigenic structure of human interferon  $\omega$ 1 (Interferon  $\omega$ 1): comparison with other human interferons," *J. Gen. Virol.* 68(6):1669-1676 (Jun. 1987).

Adolf et al., "Purification and characterization of natural human interferon  $\omega$ 1," *J. Bio. Chem.* 265(16):9290-9295 (Jun. 1990).

Adolf et al., "Human interferon  $\omega$ 1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," *Biochim. Biophys. Acta* 108(9):167-174 (Jun. 1991).

ANDRX Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).

ASTM International, *Annual Book of ASTM Standards*, 8.02:208-211, 584-587 (1984).

Ansel et al., "Dosage Form Design: Pharmaceutical and Formulation Considerations," *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).

Ansel et al., "Modified-Release Dosage Forms and Drug Delivery Systems," *Pharmaceutical Dosage Forms and Drug Delivery Systems*, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).

Aulitzky, "Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gamma," *Journal of Clinical Oncology* 7(12):1875-1884 (1989).

Hauck, "Engineer's Guide to Plastics," *Materials Engineering* 5(72):38-45 (Jul. 17, 1972).

Bailon et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C," *Bioconjugate Chemistry* 12(2):195-202 (2001).

Bakan et al., "Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography," *J. Pharm. Sci.*, 85(9):908-914 (1996).

Bakhtiar et al, "Taking Delivery," *Soap Perfumery & Cosmetics* 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).

Balkwill,F., "Interferons," *Lancet* 1(8646):1060-1063 (May 1989).

(56)

## References Cited

## OTHER PUBLICATIONS

- Bauer et al., "Non-aqueous emulsions as vehicles for capsule fillings," *Drug Dev. & Industrial Pharmacy* 10(5):699-712 (1984).
- Bekkering et al., "Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model," *Hepatology* 33(2):419-423 (Feb. 2001).
- Bell et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," *Nature* 302:716-718 (1983).
- Bell et al., "Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin," *Drug Delivery Research & Dev. Biopolymers*, (35):201-209 (1995).
- Bertoncello et al., "Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil," *Int. J. Radiat. Biol.* 67(1):57-64 (1995).
- Bohlinder et al., "Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system," *Euro. J. Pharm. Sci.* 2(4):271-279 (1994).
- Bolinger et al., "Recombinant interferon  $\gamma$  for treatment of chronic granulomatous disease and other disorders," *Clin. Pharm.* 11(10):834-850 (Oct. 1992).
- Bonkovsky et al., "Outcomes research in chronic viral hepatitis C: effects of interferon therapy," *Can. J. Gastroenterol.* 14(Supp. B):21B-29B (Jul.-Aug. 2000).
- Borden et al., "Second-generation interferons for cancer: clinical targets," *Semin. Cancer Biol.* 10(2):125-144 (Apr. 2000).
- Boué et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN- $\omega$ 1 obtained from *Pichia pastoris*," *J. Interferon & Cytokine Res.* 20:677-683 (2000).
- Buckwold et al., "Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses," *Antiviral Res.* 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
- Cantor, "Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence," *J. Chem. Physics* 104(20):8082-8095 (1996).
- CAS Number: 56-81-5 (Nov. 16, 1984).
- Chang et al., "Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer," *Pharm. Tech.* 20(1):80-84 (1996).
- Chapman et al., "Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)," *Chem. & Physics of Lipids* 1(5):445-475 (1967).
- Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," *Methods & Findings in Experimental & Clinical Pharmacology* 20(3):211-215 (1998).
- Clark et al., "The diabetic Zucker fatty rat," *Proc. Soc. Exp. Biol.* 173(1):68-75 (1983).
- Condino-Neto, "Interferon- $\gamma$  improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation," *Blood* 95(11):3548-3554 (Jun. 2000).
- Darney, "Subdermal progestin implant contraception," *Current Opinion in Obstetrics & Gynecology* 3:470-476 (1991).
- Das et al., "Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues," *BioPharm*, 2(11):44-51 (1999).
- Dash et al., "Therapeutic applications of implantable drug delivery systems," *Journal of Pharmacological and Toxicological Methods*, 40(1):1-12 (1998).
- Davis et al., "Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570)*.
- Deacon et al., "GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion," *Am. J. Physiol. Endocrinol. Metab.*, 282:E873-E879 (2002).
- Desai et al., "Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor," *J. Am. Chem. Soc.* 116(21):9420-9422 (1994).
- Di Marco et al., "Combined treatment of relapse of chronic hepatitis C with high-dose  $\alpha$ -2B interferon plus ribavirin for 6 or 12 months," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569)*.
- Dorr et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days," *J. Interferon Res.* 8:717-725 (1988).
- Uhlig et al., "The electro-osmotic actuation of implantable insulin micropumps," *J. Biomed. Materials Res.* 17:931-943 (1983).
- Efendic et al., "Overview of incretin hormones," *Horm. Metab. Res.*, 36(11-12):742-746 (2004).
- Eissele et al., "Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," *Life Sci.*, 55(8):629-634 (1994).
- Elias et al., "Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon- $\alpha$  for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study," *Cancer* 89(3):597-603 (Aug. 2000).
- Eng et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from *Heloderma suspectum* venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," *J. Biol. Chem.*, 267(11):7402-7405 (1992).
- Eng et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from *Heloderma horridum* venom," *J. Biol. Chem.*, 265(33):20259-20262 (1990).
- Eppstein et al., "Biological activity of liposome-encapsulated murine interferon  $\gamma$  is mediated by a cell membrane receptor," *PNAS USA* 82:3688-3692 (1985).
- Eros et al., "Multiple phase emulsions as controlled drug delivery therapeutic systems," *Proc.-Conf. Colloid Chem.* 193-196 (1993).
- Fang et al., "The impact of baseline liver histology on virologic response to interferon  $\alpha$ -2b $\pm$ p ribavirin therapy in patients with chronic hepatitis C," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572)*.
- Felker et al., "The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface," *J. Nutritional Biochem.* 4(1):630-634 (1993).
- Ferenci et al., "Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C," *Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977)*.
- Fontaine et al., "Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon  $\alpha$ ," *Lancet* 356(9223):41 (Jul. 2000).
- Fujii et al., "Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," *Int'l J. Pharmaceutics* 222(1):57-64 (2001).
- Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" *Diabetologia* 27:599-600 (1984).
- Glue et al., "A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571)*.
- Goke et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells," *J. Biol. Chem.*, 268(26):19650-19655 (1993).
- Gonzales et al., "Randomized controlled trial including an initial 4-week 'induction' period during one year of high-dose interferon  $\alpha$ -2B treatment for chronic hepatitis C," *Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975)*.
- Gosland et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha," *Cancer Chemother. Pharmacol.* 37(1-2):39-46 (1995).
- Grant et al., "Combination therapy with interferon- $\alpha$  plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study," *J. Med. Virol.* 61(4):439-442 (Aug. 2000).
- Gutniak et al., "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," *N. Engl. J. Med.*, 326(20):1316-1322 (1992).
- Hageman, "The Role of Moisture in Protein Stability," *Drug Dev. & Ind. Pharm.* 14(14):2047-2070 (1988).

(56)

## References Cited

## OTHER PUBLICATIONS

- Heathcote et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis," *New England J. Med.* 343(23):1673-1680 (2000).
- Heim et al., "Intracellular signaling and antiviral effects of interferons," *Dig. Liver Dis.* 32(3):257-263 (Apr. 2000).
- Heinrich et al., "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," *Endocrinol.*, 115:2176-2181 (1984).
- Hellstrand et al., "Histamine and cytokine therapy," *Acta Oncol.* 37(4):347-353 (1998).
- Hellstrand et al., "Histamine and the response to IFN- $\alpha$  in chronic hepatitis C," *Interferon Cytokine Res.* 18(1):21-22 (Jan. 1998).
- Hellstrand et al., "Histamine in immunotherapy of advanced melanoma: a pilot study," *Cancer Immunol Immunother.* 39(6):416-419 (Dec. 1994).
- Hisatomi et al., "Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals," *J. Toxicol. Sci.*, 18(3):1-9 (1993).
- Hodoshima et al., "Lipid nanoparticles for delivering antitumor drugs," *International Journal of Pharmaceutics*, 146(1):81-92 (1997).
- Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
- Horton et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" *Cancer Res* 59(16):4064-4068 (Aug. 1999).
- Hubel et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" *Leukemia 11 Suppl 5:S47-S51* (Dec. 1997).
- Iacobelli et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer," *Am. J. Clin. Oncol.* 18(1):27-31 (1995).
- IFNB Multiple Sclerosis Study Group, "Interferon $\beta$ -1b is effective in relapsing-remitting multiple sclerosis," *Neurology* 43(4):655-667 (Apr. 1993).
- Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
- "Introduction to Antibodies", <http://www.chemicon.com/resource/ANT101/a1.asp>, 8 pages (retrieved May 2, 2007).
- Isaacs et al., "Virus interference. I. The interferon," *Pro. R. Soc. Lond. B. Biol. Sci.* 147:258-267 (1957).
- Jain et al., "Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system," *J. Microencapsulation* 17(3):343-362 (2000).
- Jordan et al., "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations," *The Oncologist* 12(9):1143-1150 (2007).
- Kabalnov et al., "Macroemulsion type and stability of alkane-water-phospholipid systems," *Abstracts of Papers, Part 1, 210th ACS National Meeting, 0/8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).*
- Kabalnov et al., "Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability," *Journal of Colloid and Interface Science* 184(1):227-235 (1996).
- Khalili et al., "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C," *Am. J. Gastroenterol.* 95(5):1284-1289 (May 2000).
- Kildsig et al., "Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films," *J. Pharma. Sci.* 29(11):1634-01637 (Nov. 17, 1970).
- Kirkwood et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," *J. Clin. Oncol.* 14(1):7-17 (1996).
- Kita et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon- $\gamma$ ," *Drug Des. Deliv.* 6(3):157-0167 (Sep. 1990).
- Knepp et al., "Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor," *J. Pharm. Sci. Tech.* 50(3):163-171 (1996).
- Knepp et al., "Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures," *Pharma. Res.* 15(7):1090-1095 (1998).
- Knobler et al., "Systemic  $\alpha$ -interferon therapy of multiple sclerosis," *Neurology* 34(10):1273-1279 (Oct. 1984).
- Kovacevic et al., "Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant  $\alpha$ -2 interferon," *Maksic Dj Vojnosanit. Pregl.* 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
- Kracke et al., "Mx proteins in blood leukocytes for monitoring interferon  $\beta$ -1b therapy in patients with MS," *Neurology* 54(1):193-199 (Jan. 2000).
- Krown et al., "Interferons and interferon inducers in cancer treatment," *Semin. Oncol.* 13(2):207-217 (1986).
- Kubes et al., "Cross-species antiviral and antiproliferative activity of human interferon- $\omega$ " *J. Interferon Res.* 14:57-59 (1994).
- Kunzi et al., "Role of interferon-stimulated gene ISG-15 in the interferon- $\omega$ -mediated inhibition of human immunodeficiency virus replication," *J. Interferon Cytokine Res.* 16(11):919-927 (Nov. 1996).
- Larsson, "Stability of emulsions formed by polar lipids," *Progress in the Chemistry of Fats and Other Lipids* 16:163-0169 (1978).
- Lee et al., "Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment," *Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974).*
- Lee, "Therapy of hepatitis C: interferon alfa-2A trials," *Hepatology* 26: 89S-95S (Sep. 1997) (XP000981288).
- Lopez et al., "Mammalian pancreatic preproglucagon contains three glucagon-related peptides," *Proc. Natl. Acad. Sci. USA*, 80(18):5485-5489 (1983).
- Lukaszewski et al., "Pegylated  $\alpha$  interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection," *J. Virol.* 74(11):5006-5015 (Jun. 2000).
- Lund et al., "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem," *Proc. Natl. Acad. Sci. USA*, 79(2):345-349 (1982).
- Lundberg, "A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)," *J. Pharm. & Pharmacol.* 49(1):16-21 (1997).
- Magnuson et al "Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells," *Protein Expression & Purification* 7:220-228 (1996).
- Malley et al., "Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration," *Drug Chem Toxicol.* 24(4):315-38 (Nov. 2001).
- Manning et al, "Stability of protein pharmaceuticals," *Pharm. Res.* 6(11):903-918 (1989).
- Marincola et al., "Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," *J. Clinical Oncol.* 13(5):1110-1122 (1995) (XP009078965).
- Massey, "Interaction of vitamin E with saturated phospholipid bilayers," *Biochem. & Biophys. Res. Comms.* 106(3):842-847 (1982).
- McHutchison et al., "Interferon  $\alpha$ -2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C," *N. Engl. J. Med.* 339(21):1485-1492 (Nov. 1998).
- Meier et al., "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans," *Am. J. Physiol. Endocrinol. Metab.*, 290(6):E1118-E1123 (2006).
- Merad et al., "Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN- $\alpha$  plus IL-2 and IL-12)," *J. Immunother.* 23(3):369-378 (May-Jun. 2000).
- Milella et al., "Neutralizing antibodies to recombinant  $\alpha$ -interferon and response to therapy in chronic hepatitis C virus infection," *Liver* 13(3):146-150 (Jun. 1993).

(56)

## References Cited

## OTHER PUBLICATIONS

- Mohler, "Primer on electrodeposited coatings," *Materials Engineering* 5:38-45 (1972).
- Mojsov, "Structural requirements for biological activity of glucagon-like peptide-I," *Int. J. Peptide Protein Research*, 40:333-343 (1992).
- Morgan, "Structure and Moisture Permeability of Film-Forming Polymers," *Ind. Eng. Chem.* 45(10):2296-2306 (1953).
- Motzer et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma," *J. Clinical Oncol.* 19(5):1312-1319 (2001).
- Nauck et al., "Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients," *Diabet. Med.*, 15(11):937-945(1998).
- Neumann et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy," *Science* 282:103-107 (Dec. 1998).
- Nieforth et al., "Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon- $\alpha$ -2a and a polyethylene glycol-modified derivative in healthy subjects," *Clin. Pharmacol. Ther.* 59(6):636-646 (Jun. 1996).
- Norden et al., "Physicochemical characterization of a drug-containing phospholipid-stabilized o/w emulsion for intravenous administration," *Eur. J. Pharm. Sci.* 13(4):393-401 (2001).
- Olaso et al., "Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C," *Esp. Quimioter.* 12(3):220-228 (Sep. 1999) (non-English with English abstract).
- Ortiz et al., "A differential scanning calorimetry study of the interaction of  $\alpha$ -tocopherol with mixtures of phospholipids," *Biochim et Biophys Acta* 898(2):214-222 (1987).
- Panitch, "Interferons in multiple sclerosis," *Drugs* 44(6):946-962 (Dec. 1992).
- Patzelt et al., "Identification and processing of proglucagon in pancreatic islets," *Nature*, 282:260-266 (1979).
- Peterson et al., "Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus," *ILAR Journal*, 32(3):16-19 (1990).
- Peterson et al., "Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa)," *Frontiers in diabetes research. Lessons from Animal Diabetes III*, Shafir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990).
- Pimstone et al., "High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C," *Prog. Abstr. Dig. Dis. Week 2000*, San Diego, CA (May 21-24, 2000) (Abstract 973).
- Plauth et al., "Open-label phase II study of omega interferon in previously untreated HCV infected patients," *Hepatology* 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
- Plauth et al., "Open-label study of omega interferon in previously untreated HCV-infected patients," *J. Hepatology* 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
- Pohl et al., "Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues," *J. Biol. Chem.*, 273(16):9778-9784 (1998).
- Poynard et al., "Is an 'a la carte' combined interferon  $\alpha$  2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C," *Hepatology* 31(1):211-218 (Jan. 2000).
- Poynard et al., "Randomized trial of interferon  $\alpha$  2b plus ribavirin for 48 weeks or for 24 weeks versus interferon  $\alpha$  2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus," *Lancet* 352(9138):1426-1432 (Oct. 1998).
- "Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD," *Intarcia Therapeutics, Inc.* (Sep. 22, 2010) (Press Release).
- Quesada et al., "Interferons in Hematological Malignancies", eds. Baron et al., *U. Tex.* 487-495 (1987).
- Quintanar-Guerrero et al., "Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides," *Pharm. Res.* 14(2):119-127 (1997).
- Rajkumar et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma," *Int'l J. Radiat. Oncol. Biol. Phys.* 40(2):297-302 (Jan. 15, 1998).
- Roche Pharmaceuticals, *Roferon®-A (Interferon alfa-2a, recombinant)*, 22 pages (2003).
- Roff et al., "Handbook of Common Polymers", Cleveland Rubber Co. 72 pages (1971).
- Rogers et al., "Permeability Valves," *Ind. & Eng. Chem.* 49(11):1933-1936 (Nov. 17, 1957).
- Roman et al., "Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL," *Transplantation* 48(4):554-558 (1989).
- Roth et al., "High Dose Etrretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas," *Acta Oncol.* 38(5):613-617 (1999).
- Roth et al., "Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity," *Endocrinol.* 148(12):6054-61 (Dec. 2007).
- Schepp et al., "Exendin-4 and exendin-(9-39)NH<sub>2</sub>: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH<sub>2</sub>," *Eur. J. Pharmacol.*, 269(2):183-191 (1994).
- Schering Corp., *Intron® A for Injection*, 6 pages (2001).
- Schering Corp., *PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection*, 29 pages (2003).
- Schmalhub et al., "Modification of drug penetration into human skin using microemulsions," *J. Controlled Release* 46(3):279-285 (1997).
- Sen et al., "The interferon system: a bird's eye view of its biochemistry," *J. Biol. Chem.* 267(8):5017-5020 (Mar. 1992).
- Shiffman et al., "A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology," *Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis.*, Dallas, TX (Nov. 5-9, 1999) (Abstract 567).
- Shima et al., "Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment," *J. Gastroenterol. Hepatol.* 15(3):294-299 (Mar. 2000).
- Shiratori et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," *Ann. Int. Med.* 132(7):517-524 (Apr. 2000).
- Simon et al., "A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon  $\beta$ 1a," *Neurology* 55(2):185-192 (Jul. 2000).
- Sparks et al., "Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia," *Metabolism*, 47(11):1315-1324 (1998).
- Sulkowski et al., "Peginterferon- $\alpha$ -2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study," *Biodrugs* 16(2):105-109 (2002).
- Talpaz et al., "Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia," *Blood* 98(6):1708-1713 (2001).
- Talsania et al., "Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice," *Endocrinology* 146(9):3748-56 (Sep. 2005).
- Tanaka et al., "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients," *Int. J. Cancer* 87(5):741-749 (Sep. 2000).
- Tong et al., "Prediction of response during interferon  $\alpha$  2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison," *Hepatology* 26(6):1640-1645 (Dec. 1997).
- Touza Rey et al., "The clinical response to interferon- $\gamma$  in a patient with chronic granulomatous disease and brain abscesses due to *Aspergillus fumigatus*," *Ann. Med. Int.* 17(2):86-87 (Feb. 2000).

(56)

## References Cited

## OTHER PUBLICATIONS

- Trudeau et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer," *Cancer Chemother. Pharmacol.* 35(6):496-500 (1995).
- Tseng et al., "Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat," *PNAS USA*, 90(5):1992-1996 (1993).
- Tsung et al., "Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules," *J. Pharm. Sci.* 86(5):603-7 (May 1997).
- Unniappan et al., "Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY," *Diabetologia; Clinical and Experimental Diabetes and Metabolism* 49(8):1915-1923 (Jun. 27, 2006).
- Vokes et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest," *Cancer Chemother. Pharmacol.* 35(4):304-312 (1995).
- Vrabec, "Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing," *Otolaryngol. Head Neck Surg.*, 118(3 Pt. 1):304-308 (1998).
- Wang et al., "Preferential interaction of  $\alpha$ -tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," *Eur. J. Biochem.* 267(21):6362-6368 (2000).
- Wang et al., "Ripple phases induced by  $\alpha$ -tocopherol in saturated diacylphosphatidylcholines," *Archives of Biochem. & Biophys.* 377(2):304-314 (2000).
- Wang et al., "The distribution of  $\alpha$ -tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," *Biochimica et Biophysica Acta-Biomembranes* 1509(1-2):361-372 (2000).
- Wang et al., "Parenteral formulations of proteins and peptides: stability and stabilizers," *J. Parenter. Sci. Technol.* 42(2S):S4-S26 (1988).
- Young et al., "Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (*Macaca mulatta*)," *Diabetes*, 48(5):1026-1034 (1999).
- Younossi et al., "The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with  $\alpha$  interferons, in the treatment of chronic hepatitis C," *Semin. Liver Dis.* 19(Supp. 1):95-102 (1999).
- Yu et al., "Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog," *J. Pharm. Sci.* 85(4):396-401 (1996).
- Zeidner et al., "Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2',3'-dideoxycytidine," *Antivir. Res.* 11(3):147-0160 (Apr. 1989).
- Zein, "Interferons in the management of viral hepatitis," *Cytokines Cell Mol. Ther.* 4(4):229-241 (Dec. 1998).
- Zeuzem et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C," *New Engl. J. Med.* 343(23):1666-1672 (2000).
- Zeuzem et al., "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon  $\alpha$  on viral turnover," *Hepatology* 28(1):245-252 (Jul. 1998).
- Zhang et al., "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis," *J. Clinical Pediatrics* 14(2):83-84 (1996).
- Zhang et al., "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor," *Pharm. Res.* 12(10):1447-1452 (1995).
- Zheng et al., "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis," *Beijing Med. J.* 13(2):80-81 (1998).
- Ziesche et al., "A preliminary study of long-term treatment with interferon  $\gamma$ -1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis," *New Engl. J. Med.* 341(17):1264-1269 (Oct. 1999).
- Sanofi-Aventis U.S. LLC, Prescribing Information for Adlyxin® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages.
- Amylin Pharmaceuticals, Inc., Prescribing Information for Byetta® (Exenatide) Injection, rev. Oct. 2009, 34 pages.
- Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages.
- Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages.
- Glaxosmithkline LLC, Prescribing Information for Tanzeum® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages.
- Eli Lilly & Company, Prescribing Information for Trulicity® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages.
- Adolf, "Human interferon omega-a review," *Mult. Sclr.* 1:S44-47 (1995).
- Costantino et al., "Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability," *J. Pharm. Sci.* 91:388-395 (2002).
- Henry et al., "Comparing ITCA 650, continuous subcutaneous delivery of exenatide via Duros® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes," oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, 21 pages (Sep. 20-24, 2010).
- Huggins et al., "Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses," *Antimicrobial Agents & Chemotherapy*, 26(4):476-480 (1984).
- Ishiwata et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs," *J. Vet. Med. Sci.* 60(8):911-917 (1998).
- Johnson et al., "How interferons fight disease," *Sci. Am.* 270(5):68-75 (May 1994).
- Lublin et al., "Defining the clinical course of multiple sclerosis: results of an international survey," *Neurology*. 46:907-911 (1996).
- Madsbad, "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results," *Best Practice & Research Clinical Endocrinology & Metabolism* 23:463-77 (2009).
- Nielsen, "Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes," *Drug Discovery Today* 10(10):703-710 (May 15, 2005).
- Patti et al., "Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study," *Acta. Neurol. Scand.* 100:283-289 (1999).
- Paty et al., "Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis," *Neurology* 43:662-667 (1993).
- PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009).
- "Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1," NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release).
- Quianzon et al., "Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes," *US Endocrinology* 7(2):104-109 (2011).
- Ratner et al., "Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial," *Diabetic Medicine* 27(9):1024-1032 (Sep. 2010).
- Roberts et al., "The Evolution of the Type I Interferons 1," *J. Interferon Cytokine Res.* 18(10):805-816 (Oct. 1998).
- Rohloff et al., "DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months," *J. Diabetes Sci. & Tech.*, 2(3):461-467 (May 1, 2008).
- "Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope", [http://patentscope.wipo.int/search/docservicepdf\\_pct/id00000008776887](http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887), 1 page (last visited Nov. 14, 2012).

(56)

## References Cited

## OTHER PUBLICATIONS

- Shire et al., "Challenges in the Development of High Protein Concentration Formulations," *J. Pharm. Sci.* 93:1390-1402 (2004).
- Smith, "Peripheral Neuro-hormones as a Strategy to Treat Obesity," oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).
- Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (Apr. 15, 2011).
- Zhang et al., "Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers," *Current Physician* 2(12):45-46 (1997).
- Pratley et al., "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors," *Rev. Diabet. Stud.*, 5(2):73-94 (2008).
- Gonzalez, et al., "Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico," *Salud Publica Mex* 55:462-468 (2013).
- Ahn et al., "A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning" *Journal of Medicinal Chemistry*, vol. 44, No. 19, (2001): 3109-3116.
- Georgios, et al., "Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers", *Advances in Therapy, Health Communications, Metuchen, NJ, US*, vol. 32, No. 7, Jul. 10, 2015, pp. 650-661.
- Yu et al., "Glucagon-like peptide 1 based therapy for type 2 diabetes", *World Journal of Pediatrics* vol. 4, No. 1, Feb. 1, 2008, pp. 8-13.
- Taylor et al., "Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes", *Horm Metab Res* 37: 627-632 (2005).
- Gao et al., "Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys, And Humans," *Drug Metabolism and Disposition*, vol. 40, No. 5, pp. 990-997 (2012).
- Franchetti et al., "Furanfuran and Thiophenfuran: Two Novel Tiazofuran Analogues, Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase," *J. Medicinal Chem.* 38(19):3829-3837 (1995).
- Fujii et al., "Effect of phosphatidylethanolamine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," *Int'l J. Pharmaceutics* 222(1):57-64 (2001).
- Fujii et al "Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP)," *Int'l J. Pharmaceutics* 234(1-2):121-128 (2002).
- Luft et al., "Electro-osmotic valve for the controlled administration of drugs," *Med. & Biological Engineering & Computing* 45-50 (Jan. 1978) (non-English with English abstract).
- Gan to Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors," *Cancer & Chemotherapy* 12(4):913-920 (Apr. 1985) (non-English with English abstract).
- Gappa et al., "Juvenile laryngeal papillomatosis—a case report," *Pneumologie* 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
- Gause et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer," *J. Clin. Oncol.* 14(8):2234-2241 (Aug. 1996).
- Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" *Diabetologia* 27:599-600 (1984).
- Croxatto, "Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant," *Eur J Contracept Reprod Health Care.* Sep. 2000; 5 Suppl 2:21-8.
- Implanon\_Prescribing Information. Manufactured for Merck Sharp Dohme Corp. Copyright © 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
- Nexplanon\_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright ©Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
- Probuphine\_Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016.
- Henry et al. (2014) "Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes," *Journal of Diabetes and Its Complications*, 28:393-398.
- Schepis et al. (2001) "Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection," *Hepatology*, 33(2):333-338.

\* cited by examiner




FIG. 1




FIG. 2






FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10






FIG. 11




FIG. 12




FIG. 13




FIG. 14